References

Allen JG, Bloxham DP (1989) The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther 40:1-27

Brecher AR, Orlow SJ (2003) Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 49:171-182 Callen JP (1990) Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 8:355-365

Coburn PR, Shuster S (1982) Dapsone and discoid lupus erythematosus. Br J Dermatol 106:105-106

Coleman MD (1993) Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 129:507-513 Craven NM, Griffiths CE (1996) Topical retinoids and cutaneous biology. Clin Exp Dermatol 21:1-10

Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis

Clin North Am 21:99-115 Duken CM (1984) Retinoids: a review. J Am Acad Dermatol 11:541-552

Ellis CN, Krach KJ (2001) Uses and complications of isotretinoin therapy. J Am Acad Dermatol 45:S150-157

Furner BB (1990a) Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 29:542-547

Furner BB (1990b) Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Der-matol 29:587-590

Grupper C, Berretti B (1984) Lupus erythematosus and etretinate. In: Cunliffe WJ, Miller AJ

(eds) Retinoid therapy. MTP, Lancaster, pp 73-82 Hall RP, Lawley TJ, Smith HR, Katz SI (1982) Bullous eruption of systemic lupus erythematosus.

Ann Intern Med 97:165-170 Katz SI (1999) Sulfones. In: Freeberg MI, Eisen ZA, Wolff K, Austen FK, Goldsmith AL, Katz IS, Fitzpatrick BT (eds) Dermatology in general medicine, 5th ed. McGraw-Hill, New York, pp 2790-2794

Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: an overview of adverse effects. J Am

Acad Dermatol 41:S7-S12 Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus - a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033-1041 Lang PG Jr (1979) Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1:479-492

Lindskov R, Reymann F (1986) Dapsone in the treatment of cutaneous lupus erythematosus.

Dermatologica 172:214-217 Lo JS, Berg RE, Tomecki KJ (1989) Treatment of discoid lupus erythematosus. Int J Dermatol 28:497-507

Lubach D, Wagner G (1984) Erfolgreiche Behandlung eines subakut kutanen Lupus erythematodes mit Etretinat. Aktuel Dermatol 10:142-144 Lucek RW, Colburn WA (1989) Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 10:38-62

McCormack LS, Elgart ML, Turner ML (1984) Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 11:397-401 Miyachi Y, Niwa Y (1982) Effects of KI, colchicine and dapsone on the generation of PMNL-

derived oxygen intermediates. Br J Dermatol 107:209-214 Mok CC, Lau CS (1996) Dapsone syndrome in cutaneous lupus erythematosus. J Rheumatol 23:766-768

Mok CC, Lau CS, Wong RW (1998) Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases. J Rheumatol 25:1246-1247

Newton RC, Jorizzo JL, Solomon AR Jr, Sanchez RL, Daniels JC, Bell JD, Cavallo T (1986) Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythe-matosus. Arch Dermatol 122:170-176 Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34:459-503 Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53:358-388 Peck GL, DiGiovanna JJ (1999) Retinoids. In: Freeberg MI, Eisen ZA, Wolff K, Austen FK, Goldsmith AL, Katz IS, Fitzpatrick BT (eds) Dermatology in general medicine. 5th ed. McGraw-Hill, New York, pp 2810-2821 Pfeiffer C, Wozel G (2003) Dapsone and sulfones in dermatology: overview and update. J Am

Acad Dermatol 48:308-309 Ruzicka T, Goerz G (1981) Dapsone in the treatment of lupus erythematosus. Br J Dermatol 104:53-56

Ruzicka T,Wasserman SI, Soter NA, Printz MP (1983) Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone. J Allergy Clin Immunol 72:365-370 Ruzicka T, Meurer M, Braun-Falco O (1985) Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 65:324-329 Ruzicka T, Meurer M, Bieber T (1988) Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 124:897-902 Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 127:513-518 Shornick JK, Formica N, Parke AL (1991) Isotretinoin for refractory lupus erythematosus. J Am

Acad Dermatol 24:49-52 Wiegand UW, Chou RC (1998) Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 39:S8-12

Wiegand UW, Chou RC (1998) Pharmacokinetics of acitretin and etretinate. J Am Acad Derma-tol 39:S25-33

Windhorst DB (1982) The use of isotretinoin in disorders of keratinisation. J Am Acad Derma-tol 6:708-709

Wozel G, Barth J (1988) Current aspects of modes of action of dapsone. Int J Dermatol

27:547-552

Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45:420-434

Zuidema J, Hilbers-Modderman ES, Merkus FW (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11:299-315

Hair Loss Prevention

Hair Loss Prevention

The best start to preventing hair loss is understanding the basics of hair what it is, how it grows, what system malfunctions can cause it to stop growing. And this ebook will cover the bases for you. Note that the contents here are not presented from a medical practitioner, and that any and all dietary and medical planning should be made under the guidance of your own medical and health practitioners. This content only presents overviews of hair loss prevention research for educational purposes and does not replace medical advice from a professional physician.

Get My Free Ebook


Post a comment